The first drug for Alexander disease arrived on September 3, 2026, a quarter century after scientists found the mutation that causes it, and for the roughly 300 Americans who live with this fatal brain disease it is the thing their families have been waiting a lifetime for. It costs $1.14 million a year. And the approval handed its maker, Ionis Pharmaceuticals, a second prize on the way out the door: a federal voucher the company can turn around and sell for more than $100 million. Both things are true at once, which is what makes this approval worth slowing down over. It is a therapeutic first, and it is a test case for how much an ultra-rare drugmaker can charge when nobody in the system is positioned to say no.

ANNUAL PRICE
$1.14 millionper patient, before rebates
The list price for one year of Zanvastro, for a disease affecting about 300 Americans. Source: MedCity News, 2026

To understand why the families waited so long, and why the milestone is worth honoring even as the price invites a fight, start with what makes Alexander disease so strange. It is not a disease of neurons, the cells we usually blame when a brain fails. It is a disease of astrocytes, the star-shaped support cells that outnumber neurons and were long dismissed as the brain’s plumbing. The culprit is a protein pathologists have used for decades as their reliable marker for astrocytes: glial fibrillary acidic protein, or GFAP. In Alexander disease a mutation makes the cell produce too much of it, the excess clumps into deposits called Rosenthal fibers, and the astrocyte turns from caretaker into saboteur. We have known this since 2001, when Michael Brenner, Albee Messing and their colleagues pinned the disease to mutations in the GFAP gene in Nature Genetics, answering a puzzle first described in 1949. For infants, the natural history is brutal and short: an enlarged head, seizures, developmental collapse, and death usually within the first decade. A named cause, a visible pathology under the microscope, and for twenty-five years, nothing to give the patient.

THE LONG WAIT
1949disease first described2001GFAP mutation identified2021antisense reverses it in rats2026FDA approves the first drug
A named cause since 2001 and a proof of concept in 2021, with no approved therapy until now. Source: FDA; Nature Genetics; Science Translational Medicine

The mechanism pointed at its own fix. If the problem is too much toxic GFAP, lower the GFAP. In 2021 Messing’s lab did exactly that in a rat model, using an antisense oligonucleotide, a short strand of engineered genetic material that intercepts the GFAP message before the cell can build the protein. The drug reversed GFAP pathology, repaired white-matter damage, and rescued motor impairment in the animals. Zanvastro, generic name zilganersen, the drug the FDA just approved, uses that same antisense approach, delivered as an injection into the spinal canal every three months so it reaches the brain.

The data are thinner than the celebration suggests. Approval rested on a single controlled study, NCT04849741, enrolling just 49 patients aged two and older, with a four-patient substudy in children under two. The load-bearing result: in patients five and older who already had trouble walking, gait speed on a ten-meter walk test held steady against a declining control group at week 61, a least-squares mean difference of 33.3 percent. The p-value was 0.041. That cleared the statistical bar, with very little room to spare, on one walking measure, in a population small enough to fit in a lecture hall. Younger children gained motor skills on a standard scale while controls slipped. The common side effects ran to vomiting, back pain, cough, headache and post-lumbar-puncture syndrome, with aseptic meningitis reported. Emily Freilich, who directs the FDA’s Division of Neurology I, framed the stakes plainly, noting that until now there had been “no approved treatment options,” only “supportive care while the disease progresses.” She is right about that. The drug is a modest, narrowly significant answer to a disease that had no answer at all.

PIVOTAL GAIT RESULT
33.3 percentwalk-speed gap vs control at week 61
The load-bearing efficacy result, at p=0.041, from a 49-patient trial. Source: NeurologyLive, 2026

Now the part the celebration walks past. Ionis set the price at $285,000 per dose, and at four doses a year that is $1.14 million annually before rebates, for a disease the company itself estimates affects about 300 people in the United States. The sell-side analysts at William Blair called the price higher than expected and still projected peak U.S. sales near $160 million by 2040, precisely because they do not expect payers to push back against an ultra-orphan therapy with no alternative. That is the ultra-orphan pricing model said out loud: charge what the absence of competition will bear, and count on the fact that no insurer wants to be the one refusing a child the only drug for a fatal disease.

Then comes the bonus. Because Alexander disease qualifies as a rare pediatric disease, the approval also handed Ionis a priority review voucher, a tradeable coupon that lets whoever holds it jump the FDA queue on some future application. Recent vouchers have sold on the open market for $100 million or more, and Congress reauthorized the program through September 2029 after letting it lapse. Sit with that arithmetic: a one-time, taxpayer-created voucher worth $100 million is most of the $160 million in peak annual sales analysts think the drug itself will ever reach. Ionis, holding about $2.1 billion in cash, has not said whether it will use the voucher or sell it. The incentive is doing precisely what it was built to do, and it is worth asking who captures most of the value when it does.

WHAT THE APPROVAL IS WORTH TO IONIS ($ millions)
Priority review voucher (resale)100Peak U.S. sales projected by 2040160
A one-time voucher can equal most of the drug's projected peak annual sales. Source: FiercePharma; William Blair via MedCity News

This is also the first neurology drug Ionis is selling on its own, rather than through Biogen as it did with Spinraza and Qalsody. That signals Zanvastro is meant to be a template, the first pillar of a rare-disease franchise built on the same antisense chemistry.

So watch three things, and watch them against the tension this approval set up: the families finally got their drug, Ionis got monopoly pricing plus a federal asset it can flip, and the open question is whether anyone downstream ever says no. Watch whether Ionis sells that voucher and for how much, which will price the government’s fast-pass window in public. Watch the second-half-of-2027 readout for obudanersen, the company’s antisense candidate for Angelman syndrome, which will show whether this is the start of a franchise or a one-off. And watch whether a single major payer contests the $1.14 million sticker, because until one does, the price is not something the market set. It is a number Ionis chose, and everyone downstream agreed not to argue with.

Sources

  1. FDA – FDA Approves First Drug to Treat Alexander Disease (Sept. 3, 2026)
  2. Ionis Pharmaceuticals – Zanvastro (zilganersen) approval announcement
  3. MedCity News – Ionis wins FDA approval for ultra-rare Alexander disease drug (pricing, patient count, cash position, analyst projection, obudanersen readout)
  4. NeurologyLive – FDA Approves Zilganersen, First Treatment for Alexander Disease (trial design and gait endpoint)
  5. Nature Genetics via PubMed – Brenner et al., GFAP mutations associated with Alexander disease (2001)
  6. Science Translational Medicine – Antisense therapy reverses GFAP pathology and motor impairment in a rat model of Alexander disease (2021)
  7. GeneReviews (NCBI) – Alexander Disease: clinical features and natural history
  8. FDA – Rare Pediatric Disease Designation and Priority Review Voucher Programs
  9. Spencer Fane – Congress Extends Rare Pediatric Disease Priority Review Voucher Program Through 2029
  10. FiercePharma – Rocket nets $180M in priority review voucher sale (recent PRV market prices)